ESLICARBAZEPINE ACETATE | A211246 | LUPIN LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Bial - Portela & CA S.A., et al v. Lupin Limited, et al 6 patentsANDA 211246eslicarbazepine acetate | D. Del. | 2018-02-23 | Terminated 2020-12-29 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$1.77
per ea
Lowest NADAC/Unit
$1.52
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68180029006ESLICARBAZEPINE 200 MG TABLET | $1.77 | EA | Generic | — | 2026-10-21 |
| 68180029106ESLICARBAZEPINE 400 MG TABLET | $1.67 | EA | Generic | — | 2026-10-21 |
| 68180029207ESLICARBAZEPINE 600 MG TABLET | $1.62 | EA | Generic | — | 2026-10-21 |
| 68180029306ESLICARBAZEPINE 800 MG TABLET | $1.52 | EA | Generic | — | 2026-10-21 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.